Actuate Therapeutics, Inc. (ACTU) is a clinical-stage biopharmaceutical company based in Fort Worth, Texas, developing elraglusib, a GSK-3 inhibitor being studied in metastatic pancreatic cancer and pediatric malignancies. The company has no product revenue and funds itself entirely through equity issuance. On Wednesday, the shares traded at $0.2009, down 19.64% from the previous close of $0.25, confirming a decisively negative session. No fresh corporate announcement explained the move; instead, the selling extended a decline set in motion by verified disclosures made over the past three weeks, most recently the third-quarter filing on November 13.
No new company press release, SEC filing or analyst revision surfaced during Wednesday's session. That makes today's action a continuation of an existing downtrend rather than a reaction to breaking news. The shares have now fallen in five consecutive sessions and are down roughly 96% from their 52-week high of $7.90 and about 30% in the past week alone. When a micro-cap trades on no news, price discovery is dominated by the standing overhang of dilution and financing risk, and that is the pattern visible here: each bounce is sold, and each new low triggers further stop-loss and momentum-driven selling.
The most recent verified fundamental development was the November 13 quarterly report, which showed cash and equivalents of just $2.1 million at September 30, down from $13.2 million at the start of the year. Total stockholders' equity flipped to a deficit of roughly $0.8 million, and the accumulated deficit reached $168.5 million. Management stated that substantial doubt exists about the company's ability to continue as a going concern. The reported quarterly loss of $0.14 per share beat the $0.17 consensus, but the beat was driven by lower research and administrative spending rather than by any change in the business, which is why it failed to support the stock.
October's underwritten offering added approximately 31 million shares plus roughly 15.5 million warrants at a $0.45 strike, priced at $0.71 per two shares — an effective $0.355 per share. With the over-allotment exercised on November 13, net proceeds reached about $11.8 million, but the share count jumped to 60.4 million from roughly 24 million at mid-year, more than doubling the float in a single transaction. Existing holders absorbed immediate, substantial dilution, and the warrants represent a continuing supply of stock into any rally. Further issuance remains plausible given the cash position and the company's at-the-market and committed equity facilities.
On October 28 the company disclosed a Nasdaq notice that its bid price had closed below $1.00 for 30 consecutive business days, giving it until April 26, 2027 to regain compliance, alongside a separate market-value deficiency with a January 11, 2027 deadline. Trading at $0.20, the stock is far from the $1.00 threshold, and a reverse split — the usual remedy — would not change the underlying fundamentals. For institutional holders with mandates that restrict sub-$1 or low-priced securities, the notice functions as a sell signal.
Volume was running several times its typical daily pace, with more than 2 million shares changing hands by early afternoon against a recent average closer to 400,000, a sign that the move was driven by real order flow rather than a thin print. The decline was idiosyncratic: no comparable collapse appeared across small-cap biotechnology or broad healthcare benchmarks, and peers were broadly stable. Technically, the stock broke beneath its prior 52-week low of $0.2289 and the $0.20 round number, printing a new all-time low near $0.174 before recovering to roughly $0.20. It trades well below every major moving average, and the rebound off the low is consistent with short-term bargain hunting rather than a change in trend. Market capitalization is now approximately $12 million.
The scale runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. ACTU earns 36 out of 100. The verified news backdrop is material for a company this size — going-concern doubt, a doubling of the share count and a listing deficiency — but none of it was new on Wednesday, so the fundamental component stays moderate. The price move was roughly 2.6 times the stock's average absolute daily change of about 7.6% over the past 60 sessions, and a decline of this size occurred only three times in that window. Moderately material news and a moderately unusual move combine into a middling score.
Attention turns to the company's cash position and any further financing, with the next scheduled quarterly report not expected until late March 2027. Investors will watch for updates on the oral elraglusib Phase 1/2 program, which received FDA clearance to proceed earlier this year, and for any announcement on regaining Nasdaq compliance ahead of the January and April deadlines. Analyst coverage remains nominally bullish, with a Buy consensus and targets set before the October dilution, and a reiteration this week carried a double-digit target — a gap that has so far done nothing to halt the selling. The principal risks are further equity issuance, warrant exercises adding supply, and the possibility that the cash runway forces a transaction on unfavorable terms.
Tickeron maintains hundreds of AI trading bots that cover thousands of tickers, but the Trending AI Robots page narrows that universe to the strategies performing best under current market conditions. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the curated list offers a practical starting point for comparing live results rather than theoretical backtests. For traders looking to pair volatility like ACTU's with systematic execution, it is worth a closer look at the current leaders.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ACTU declined for three days, in 151 of 159 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ACTU entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for ACTU just turned positive on November 04, 2026. Looking at past instances where ACTU's MACD turned positive, the stock continued to rise in 14 of 18 cases over the following month. The odds of a continued upward trend are 78%.
Following a +8.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACTU advanced for three days, in 89 of 99 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.982) is normal, around the industry mean (3.592). P/E Ratio (-0.378) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. ACTU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACTU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology